DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1HH — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1HH maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1hh is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1994 follow-up of 235 patients aged 16–70 enrolled on a register from 1978 to 1992 found that two-year and four-year survival improved across three consecutive five-year periods. In the earliest period (1978–1982, 26 patients) survival was 73.8% and 53.8%; in the middle period (1983–1987, 65 patients) it was 87.7% and 72.3%; in the latest period (1988–1992, 144 patients) it was 90.3% and 82.9% (P = 0.02). Patients in later periods were younger and less severely affected, which partly explained the improvement, but the survival benefit remained significant after stratification for disease severity. A progressively higher proportion of patients received ACE inhibitors and later beta blockers. In the middle group, patients treated with ACE inhibitors showed better survival than those not treated, after stratification for heart failure severity. In the latest group, beta blockers had a significant additive effect with conventional therapy: four-year survival in patients with mild heart failure treated with beta blockers (and usually digitalis and ACE inhibitors) was 90%, and in those with moderate to severe heart failure it was 87.5%.
A 1989 review stated that the natural history of dilated cardiomyopathy varies from death within two years in 50% of patients to survival beyond ten years in 25%. It noted that at least 11,000 new cases are diagnosed each year in the United States and that traditional therapy included cardiac glycosides and diuretics. A 2002 review described idiopathic dilated cardiomyopathy as a common but mystifying cause of heart failure and reviewed diagnostic and therapeutic options without presenting new data. A 2023 review reported that heart failure remains a leading cause of morbidity and mortality globally, that a new case is diagnosed in India every 23 seconds, and that only 25%–40% of patients with dilated cardiomyopathy receive guideline-directed medical therapy after diagnosis.
Two 2025 articles (apparently identical) reported a study of 200 patients divided into three age groups and emphasised age-related features of diagnosis and treatment, as well as individualisation of therapy based on age and comorbidities. No specific survival or response rates were given. The abstracts do not report any randomised trial of a repurposed drug for dilated cardiomyopathy. What is still missing is a dedicated, adequately powered trial that stratifies patients by age, disease severity, and genetic subtype, and that tests a specific repurposed agent against placebo or standard care with long-term follow-up. Funding for such a trial and a clear biomarker strategy to identify likely responders remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Heart · 1994 · 76 citations · open access
Changing mortality in dilated cardiomyopathy
AbstractOBJECTIVE: To analyse the changes in mortality in dilated cardiomyopathy over the past 15 years and to identify the factors that might have influenced survival. DESIGN: Follow up study of 235 patients (aged 16-70) systematically enrolled on a register from 1 January 1978 to 31 December 1992. SETTING: Hospital department of cardiology. PATIENTS: Three groups corresponding to three periods of 5 years: group 1 (diagnosis between 1 January 1978 and 31 December 1982) 26 patients; group 2 (diagnosis between 1 January 1983 and 31 December 1987) 65 patients; and group 3 (diagnosis between 1 January 1988 and 31 December 1992) 144 patients. MAIN OUTCOME MEASURES: Death or heart transplantation. RESULTS: Two and four year survival was 73.8% and 53.8% in group 1, 87.7% and 72.3% in group 2, and 90.3% and 82.9% in group 3 (P = 0.02). During the 15 years of the study period the number of cases increased progressively and the baseline clinical characteristics changed (that is, patients were younger and less severely affected), partly explaining the improvement in survival. None the less, the three mortality curves tended to diverge progressively and the improvement in survival in the different groups was still significant after stratification for the severity of the disease, suggesting that treatment had a sustained effect. A progressively higher proportion of patients were treated with angiotensin converting enzyme (ACE) inhibitors and more recently with beta blockers. In group 2, after stratification for the severity of heart failure, patients who were treated with ACE inhibitors showed a better survival than patients who were not. Furthermore, analysis of group 3 showed that beta blockers had a significant additive effect with conventional therapy both by intention to treat and actual treatment. Four year survival in patients with mild and moderate to severe heart failure treated with beta blockers, and usually digitalis and ACE inhibitors, was respectively 90% and 87.5%. CONCLUSIONS: The improvement in the survival of patients with dilated cardiomyopathy over the past 15 years may be explained by earlier diagnosis, new treatments, and a change in the clinical characteristics of the patients at enrolment.
Cleveland Clinic Journal of Medicine · 2002 · 44 citations
Idiopathic dilated cardiomyopathy: a common but mystifying cause of heart failure.
AbstractWhile researchers try to elucidate the origins of idiopathic dilated cardiomyopathy, clinicians continue to face the challenges of identifying and treating the causes of this condition to improve symptoms and survival. We review classification schemes for dilated cardiomyopathy and the current range of diagnostic and therapeutic options and treatment goals.
New England Journal of Medicine · 1989 · 10 citations
Immunosuppression for Dilated Cardiomyopathy
AbstractThe diagnosis of dilated cardiomyopathy is made when left ventricular dilatation and systolic dysfunction, with normal wall thickness, occur in the absence of coronary artery, valvular, or pericardial disease.1 The right ventricle is also often involved. The natural history of the disease varies from a course progressing to death within 2 years in 50 percent of afflicted patients2 to survival for more than 10 years in 25 percent. The incidence of dilated cardiomyopathy is increasing; at least 11,000 new cases are diagnosed each year in the United States. The traditional approach to therapy includes cardiac glycosides and diuretics. Although increased . . .
Heart failure journal of India · 2023 · 0 citations · open access
Management of non-ischemic dilated cardiomyopathy
AbstractHeart failure (HF) remains a leading cause of morbidity and mortality globally. For every 23 s, a new case of HF is diagnosed in India. Dilated cardiomyopathy is characterized by dilatation of the left ventricle or both ventricles with impaired function, which cannot be fully explained by abnormal loading conditions or coronary artery disease. The heterogeneity in etiology and clinical presentation of dilated cardiomyopathy makes timely diagnosis and treatment challenging. Even after diagnosis, only 25%–40% receive guideline-directed medical therapy.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
DILATED CARDIOMYOPATHY IN PATIENTS OF DIFFERENT AGE GROUPS DIAGNOSTIC AND TREATMENT FEATURES
AbstractDilated cardiomyopathy (DCM) is a severe myocardial disorder characterized by progressive dilation and dysfunction of the left ventricle, ultimately leading to heart failure. This article examines the age-related features of the manifestation, diagnosis, and treatment of DCM. The study is based on an analysis of data from 200 patients divided into three age groups. Key diagnostic markers are highlighted, including echocardiographic parameters and laboratory findings, as well as specific treatment approaches utilizing modern therapeutic strategies. Particular attention is paid to the individualization of treatment based on age and the presence of comorbidities.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
DILATED CARDIOMYOPATHY IN PATIENTS OF DIFFERENT AGE GROUPS DIAGNOSTIC AND TREATMENT FEATURES
AbstractDilated cardiomyopathy (DCM) is a severe myocardial disorder characterized by progressive dilation and dysfunction of the left ventricle, ultimately leading to heart failure. This article examines the age-related features of the manifestation, diagnosis, and treatment of DCM. The study is based on an analysis of data from 200 patients divided into three age groups. Key diagnostic markers are highlighted, including echocardiographic parameters and laboratory findings, as well as specific treatment approaches utilizing modern therapeutic strategies. Particular attention is paid to the individualization of treatment based on age and the presence of comorbidities.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
